Mind + Muscle

technical minds + legal muscle


dig deep

USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent Licensed to Regulus

  • 01.07.13
  • Sterne, Kessler, Goldstein & Fox

Sterne Kessler client Santaris Pharma A/S announces that the U.S. Patent and Trademark Office has granted its request for an inter partes reexamination of a patent licensed to Regulus Therapeutics Inc.

U.S. patent number 7,838,504 claims right to a method of reducing viral genome amount in a cell infected with Hepatitis C. The Order issued by the USPTO states that Santaris' request "establishes a reasonable likelihood that Santaris will prevail" with respect to the claims under reexamination. Additionally, the USPTO issued an Office Action that rejected the reexamined claim.

The Santaris Pharma A/S patent reexamination team is led by Eric K. Steffe of Sterne, Kessler, Goldstein & Fox, P.L.L.C.


Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.